Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2014-09-04
Target enrollment:
Participant gender:
Summary
This study of AMG 900 will be conducted in two parts: dose escalation and dose expansion. The
dose escalation part of the study is aimed at evaluating the safety, tolerability and PK
(pharmacokinetics) of oral AMG 900 in subjects with acute myeloid leukemia. Up to 93 subjects
may be enrolled in dose escalation. The dose expansion part of the study will consist of 20
subjects with acute myeloid leukemia. The dose of AMG 900 will be dependent upon data from
the dose escalation part of the study.